Clinical Trial

A Causal Role for Voltage-gated Cav1.2 Calcium Channels in Mediating 5G FR1 Effects on Sleep-associated Brain Health in Humans

Study acronym: 5G Cav12 Sleep
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 31, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
Electromagnetic fields (EMFs) generated by the use of 5G technology influence certain sleep characteristics, especially in individuals carrying a specific genetic variant of a protein in the brain that regulates the activity of nerve cells. This protein is a voltage-gated calcium channel called CaV1.2 and could be involved in the effects of 5G technology on sleep. The calcium channel CaV1.2 can be selectively blocked by the drug nimodipine. To demonstrate that CaV1.2 is indeed involved in the effects of 5G technology on sleep, the researchers are investigating in this study, with healthy subjects carrying the sought-after genetic variant, whether the administration of nimodipine and thus the blockade of the calcium channel before exposure mitigates or eliminates the effects of EMF on sleep health.
Trial Details
NCT Number NCT06998368
Lead Sponsor Hans-Peter Landolt
Collaborators: Federal Office for the Environment, Switzerland
Conditions Mediation of 5G Effects on Sleep
Enrollment 30 participants
Start Date 2024-10-22
Primary Completion 2026-06 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-31